LaNova Medicines

Company snapshot

Founded in 2019 in Shanghai, China, LaNova Medicines is a clinical-stage biotechnology company committed to the discovery and development of novel biologic drugs for cancer treatment. Led by industry veterans with a strong passion for innovation, we aim to operate as an R&D engine and deliver transformative medicines to address the unmet clinical needs of cancer patients. Leveraging our proprietar

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for LaNova Medicines. Not investment advice.

• What is LaNova Medicines?

  LaNova Medicines is a pharma organization headquartered in CN. Primary therapeutic focus areas include Advanced Solid Tumor. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO so

• Is LaNova Medicines publicly traded?

  LaNova Medicines appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does LaNova Medicines develop or market?

  No drug profiles are currently linked to LaNova Medicines. Pipeline programs may still list investigational assets.

• What are the latest developments for LaNova Medicines?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does LaNova Medicines focus on?

  LaNova Medicines focuses on Advanced Solid Tumor based on our analysis of their pipeline programs and drug development activities.